SEC Company Response from Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219) (DCOY) — Aug 11, 2025
Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219)
Date: Aug. 11, 2025 · CIK: 0001615219 · Accession: 0001615219-25-000093
AI Filing Summary & Sentiment
File numbers found in text: 333-284368
Letter
Document
SALARIUS PHARMACEUTICALS, INC.
2450 Holcombe Blvd., Suite X
Houston, Texas 77021
August 11, 2025
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Salarius Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended
File No. 333-284368
Withdrawal of Acceleration Request
Ladies and Gentlemen:
Salarius Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests the withdrawal of its acceleration request letter filed as correspondence via EDGAR transmission on August 8, 2025, which requested that the above-referenced registration statement (the “Registration Statement”) become effective on August 11, 2025, at 9:00 a.m., Eastern Time, or as soon thereafter as practicable. The Company is no longer requesting that such Registration Statement be declared effective at this specific date and time and the Company hereby formally withdraws its request for acceleration of the effective date as stated above.
Please contact Stephen Nicolai of Hogan Lovells US LLP, counsel to the Company, at (267) 675-4642 if you have any questions or concerns regarding this matter.
Very truly yours,
SALARIUS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm Document SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite X Houston, Texas 77021 August 11, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Salarius Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended File No. 333-284368 Withdrawal of Acceleration Request Ladies and Gentlemen: Salarius Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests the withdrawal of its acceleration request letter filed as correspondence via EDGAR transmission on August 8, 2025, which requested that the above-referenced registration statement (the “Registration Statement”) become effective on August 11, 2025, at 9:00 a.m., Eastern Time, or as soon thereafter as practicable. The Company is no longer requesting that such Registration Statement be declared effective at this specific date and time and the Company hereby formally withdraws its request for acceleration of the effective date as stated above. Please contact Stephen Nicolai of Hogan Lovells US LLP, counsel to the Company, at (267) 675-4642 if you have any questions or concerns regarding this matter. Very truly yours, SALARIUS PHARMACEUTICALS, INC. By: /s/ Mark J. Rosenblum Name: Mark J. Rosenblum Title: Chief Financial Officer Title: Chief Financial Officer cc: David J. Arthur, Salarius Pharmaceuticals, Inc. Stephen Nicolai, Hogan Lovells US LLP Michael F. Nertney, Ellenoff Grossman & Schole LLP Thomas Fugnitti, Ellenoff Grossman & Schole LLP